Drug Profile

BRM 424

Alternative Names: BRM-424

Latest Information Update: 27 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MacKay Memorial Hospital
Developer BRIM Biotechnology
Class Peptides
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Neurotrophic keratopathy
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Neurotrophic keratopathy

Most Recent Events

27 Jul 2023 Phase-II clinical trials in Neurotrophic keratopathy in USA (Ophthalmic) (NCT05927428)
03 Jul 2023 BRIM Biotechnology plans a phase II trial in Neurotrophic keratopathy in September 2023 (Ophthalmic) (NCT05927428) (BRIM Biotechnology pipeline, July 2023)
03 Jul 2023 BRM 424 is available for licensing as of 12 Jul 2023. https://www.brimbiotech.com/about-us/ (BRIM Biotechnology website, July 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com